RxDoctor Payments Data

Mohammad Rahman, MD

Internal Medicine · Hollis, NYNPI 1295859023

Payments from drug & device makers

$629in general payments, 2019–2025

Across 17 payments — averaging $37.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$146
  • GSK$125
  • Exact Sciences$100
  • Phathom Pharmaceuticals, Inc.$55
  • Bayer$53
  • AbbVie$42
  • plus $107 from 4 others

What the payments were for

  • Food & beverage$629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$629 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$3,603
Medicare patients
23
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$57,454
JanuviaSitagliptin Phosphate60$53,144
FarxigaDapagliflozin Propanediol16$15,051
KerendiaFinerenone16$14,725
TradjentaLinagliptin23$14,447
JanumetSitagliptin Phos/Metformin Hcl14$13,740
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$10,083
EliquisApixaban12$9,956
Diclofenac Sodium34$7,311
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,153
SymbicortBudesonide/Formoterol Fumarate16$3,145
Atorvastatin Calcium188$2,560
Halobetasol Propionate31$2,387
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,975
Metoprolol Succinate97$1,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$53$14,72516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hollis

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →